Trial Profile
A Phase II, Multicenter, Single-arm Study to Evaluate Safety and Efficacy of X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Ensartinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 15 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Jul 2023 Planned End Date changed from 1 Dec 2018 to 1 Dec 2023.
- 13 Sep 2022 Results (n=482) of a Pop PK model development analysis from four clinical trials: BTP-28311, X396-CLI-101, X396-CLI-301, and BTP-42322 presented at the 47th European Society for Medical Oncology Congress